Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib
- 31 May 2006
- journal article
- case report
- Published by Elsevier BV in Lung Cancer
- Vol. 52 (2), 253-255
- https://doi.org/10.1016/j.lungcan.2006.01.008
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1αJournal of Biological Chemistry, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceJournal of Clinical Oncology, 2005
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistanceAnnals of Oncology, 2004